Recursion Pharmaceuticals Analyst Ratings
Recursion Pharmaceuticals Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/09/2023 | 186.81% | Needham | $17 → $15 | Maintains | Buy |
09/05/2023 | 225.05% | Needham | → $17 | Reiterates | Buy → Buy |
08/09/2023 | 225.05% | Needham | → $17 | Reiterates | Buy → Buy |
07/21/2023 | 225.05% | Needham | → $17 | Reiterates | Buy → Buy |
07/18/2023 | 225.05% | Needham | → $17 | Reiterates | Buy → Buy |
07/13/2023 | 110.33% | Morgan Stanley | $8 → $11 | Maintains | Equal-Weight |
07/13/2023 | 186.81% | Keybanc | $12 → $15 | Maintains | Overweight |
07/12/2023 | 225.05% | Needham | → $17 | Reiterates | Buy → Buy |
07/12/2023 | 530.98% | Berenberg | $33 → $33 | Reiterates | Buy → Buy |
05/09/2023 | 225.05% | Needham | → $17 | Reiterates | → Buy |
05/09/2023 | 129.45% | Keybanc | $20 → $12 | Maintains | Overweight |
04/18/2023 | 225.05% | Needham | → $17 | Reiterates | → Buy |
03/16/2023 | 225.05% | Needham | → $17 | Initiates Coverage On | → Buy |
01/23/2023 | 52.96% | SVB Leerink | $9 → $8 | Maintains | Market Perform |
11/09/2022 | 72.08% | Goldman Sachs | $8 → $9 | Maintains | Neutral |
10/25/2022 | 72.08% | SVB Leerink | $10 → $9 | Maintains | Market Perform |
09/16/2022 | 282.41% | Keybanc | → $20 | Initiates Coverage On | → Overweight |
08/11/2022 | 52.96% | Goldman Sachs | $7 → $8 | Maintains | Neutral |
05/24/2022 | 33.84% | Goldman Sachs | $9 → $7 | Maintains | Neutral |
05/12/2022 | 72.08% | Goldman Sachs | $10 → $9 | Maintains | Neutral |
04/18/2022 | — | B of A Securities | Downgrades | Buy → Neutral | |
03/24/2022 | 91.2% | Goldman Sachs | $32 → $10 | Maintains | Neutral |
03/04/2022 | 91.2% | SVB Leerink | $32 → $10 | Downgrades | Outperform → Market Perform |
12/08/2021 | 511.85% | SVB Leerink | $30 → $32 | Maintains | Outperform |
09/21/2021 | 607.46% | Berenberg | → $37 | Initiates Coverage On | → Buy |
08/16/2021 | 473.61% | SVB Leerink | $33 → $30 | Maintains | Outperform |
05/11/2021 | 530.98% | SVB Leerink | → $33 | Initiates Coverage On | → Outperform |
05/11/2021 | 492.73% | B of A Securities | → $31 | Initiates Coverage On | → Buy |
05/11/2021 | 511.85% | JP Morgan | → $32 | Initiates Coverage On | → Neutral |
05/11/2021 | 550.1% | Goldman Sachs | → $34 | Initiates Coverage On | → Neutral |
05/11/2021 | 588.34% | Keybanc | → $36 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/09/2023 | 186.81% | 尼德姆 | 17 美元 → 15 美元 | 维护 | 买 |
09/05/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | 购买 → 购买 |
08/09/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | 购买 → 购买 |
07/21/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | 购买 → 购买 |
07/18/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | 购买 → 购买 |
07/13/2023 | 110.33% | 摩根士丹利 | 8 美元 → 11 美元 | 维护 | 重量相等 |
07/13/2023 | 186.81% | Keybanc | 12 美元 → 15 美元 | 维护 | 超重 |
07/12/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | 购买 → 购买 |
07/12/2023 | 530.98% | 贝伦贝格 | 33 美元 → 33 美元 | 重申 | 购买 → 购买 |
05/09/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | → 购买 |
05/09/2023 | 129.45% | Keybanc | 20 美元 → 12 美元 | 维护 | 超重 |
04/18/2023 | 225.05% | 尼德姆 | → 17 美元 | 重申 | → 购买 |
03/16/2023 | 225.05% | 尼德姆 | → 17 美元 | 启动覆盖范围开启 | → 购买 |
2023 年 1 月 23 日 | 52.96% | SVB Leerink | 9 美元 → 8 美元 | 维护 | 市场表现 |
11/09/2022 | 72.08% | 高盛 | 8 美元 → 9 美元 | 维护 | 中立 |
10/25/2022 | 72.08% | SVB Leerink | 10 美元 → 9 美元 | 维护 | 市场表现 |
2022 年 9 月 16 日 | 282.41% | Keybanc | → 20 美元 | 启动覆盖范围开启 | → 超重 |
08/11/2022 | 52.96% | 高盛 | 7 美元 → 8 美元 | 维护 | 中立 |
2022 年 5 月 24 日 | 33.84% | 高盛 | 9 美元 → 7 美元 | 维护 | 中立 |
05/12/2022 | 72.08% | 高盛 | 10 美元 → 9 美元 | 维护 | 中立 |
04/18/2022 | — | B of A 类证券 | 降级 | 买入 → 中性 | |
2022 年 3 月 24 日 | 91.2% | 高盛 | 32 美元 → 10 美元 | 维护 | 中立 |
03/04/2022 | 91.2% | SVB Leerink | 32 美元 → 10 美元 | 降级 | 跑赢大盘 → 市场表现 |
2021 年 8 月 12 日 | 511.85% | SVB Leerink | 30 美元 → 32 美元 | 维护 | 跑赢大盘 |
09/21/2021 | 607.46% | 贝伦贝格 | → 37 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 8 月 16 日 | 473.61% | SVB Leerink | 33 美元 → 30 美元 | 维护 | 跑赢大盘 |
05/11/2021 | 530.98% | SVB Leerink | → 33 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
05/11/2021 | 492.73% | B of A 类证券 | → 31 美元 | 启动覆盖范围开启 | → 购买 |
05/11/2021 | 511.85% | 摩根大通 | → 32 美元 | 启动覆盖范围开启 | → 中立 |
05/11/2021 | 550.1% | 高盛 | → 34 美元 | 启动覆盖范围开启 | → 中立 |
05/11/2021 | 588.34% | Keybanc | → 36 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Recursion Pharmaceuticals (RXRX)?
Recursion Pharmicals(RXRX)的目标价格是多少?
The latest price target for Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by Needham on November 9, 2023. The analyst firm set a price target for $15.00 expecting RXRX to rise to within 12 months (a possible 186.81% upside). 14 analyst firms have reported ratings in the last year.
Needham于2023年11月9日公布了递归制药(纳斯达克股票代码:RXRX)的最新目标股价。该分析公司将目标股价定为15.00美元,预计RXRX将在12个月内升至12个月内(可能上涨186.81%)。去年有14家分析公司公布了评级。
What is the most recent analyst rating for Recursion Pharmaceuticals (RXRX)?
Recursion Pharmicals(RXRX)的最新分析师评级是多少?
The latest analyst rating for Recursion Pharmaceuticals (NASDAQ: RXRX) was provided by Needham, and Recursion Pharmaceuticals maintained their buy rating.
Recursion Pharmicals(纳斯达克股票代码:RXRX)的最新分析师评级由Needham提供,Recursion Pharmicals维持买入评级。
When is the next analyst rating going to be posted or updated for Recursion Pharmaceuticals (RXRX)?
Recursion Pharmicals(RXRX)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Recursion Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Recursion Pharmaceuticals was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Recursion Pharmicals的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Recursion Pharmicals的最新评级是在2023年11月9日发布的,因此您应该预计下一个评级将在2024年11月9日左右公布。
Is the Analyst Rating Recursion Pharmaceuticals (RXRX) correct?
分析师对递归药业 (RXRX) 的评级是否正确?
While ratings are subjective and will change, the latest Recursion Pharmaceuticals (RXRX) rating was a maintained with a price target of $17.00 to $15.00. The current price Recursion Pharmaceuticals (RXRX) is trading at is $5.23, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但递归制药(RXRX)的最新评级维持不变,目标股价为17.00美元至15.00美元。递归制药(RXRX)目前的交易价格为5.23美元,超出了分析师的预期区间。